UNSPSC 51182700: Combination oral hypoglycemic agents

This classification denotes combination drugs and preparations which lower blood glucose levels, which patients can swallow by pill or liquid, and which therefore bear the term ORAL HYPOGLYCEMIC AGENTS. Practitioners deploy these agents against diabetes. Typical constituents are glimepiride, glipizide, glyburide, metformin, etc. Typical combination oral hypoglycemic agent constituents are glimepiride, glipizide, glyburide, and metformin.

UNSPSC 51182700 Combination oral hypoglycemic agents is a Class code that does not align with the recent state and local procurement activity posted under it. The two recent opportunities on record — Seminole County, Florida's IFB for naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's RFI for direct-to-manufacturer prescription programs — involve emergency-response pharmaceuticals and pharmacy benefit management infrastructure rather than oral diabetes medications. The mismatch suggests either a tagging error in the source system or that the code is not actively used by state and local buyers for its nominal scope. No recent solicitations for combination oral hypoglycemic agents themselves appear in the available record.

Without substantive activity under the code's stated scope, a pursue decision cannot be grounded in current market signals. If your firm has capability in diabetes-medication supply or state pharmaceutical contracting, monitor the code for corrected tagging or new opportunities; the two misfiled records do show that state health departments and county health systems are actively buying pharmaceuticals and pharmaceutical-access services. Direct clarification with procurement offices in target states on how they classify oral hypoglycemic procurement would be more productive than tracking this code as currently tagged.